Investors | Syncona

Unless stated all financials at 31 December 2023

£1.2bn

Net assets

188p

NAV per share

0.9%

NAV per share growth over previous 9 months

£700m

Value of life science portfolio

3.0%

Return from life science portfolio over previous 9 months

£551m

Capital pool

Transaction in Own Shares

25.04.24

Transaction in Own Shares

24.04.24

Transaction in Own Shares

23.04.24

Transaction in Own Shares

22.04.24

Transaction in Own Shares

19.04.24

Transaction in Own Shares

18.04.24

Transaction in Own Shares

17.04.24

Transaction in Own Shares

16.04.24

Transaction in Own Shares

15.04.24

Transaction in Own Shares

12.04.24

Century Therapeutics to acquire Clade Therapeutics

11.04.24

Transaction in Own Shares

11.04.24

Transaction in Own Shares

10.04.24

Transaction in Own Shares

09.04.24

Transaction in Own Shares

08.04.24

Transaction in Own Shares

05.04.24

Achilles reports full year 2023 Financial Results

04.04.24

Achilles provides clinical data update

04.04.24